Who, what,
and why.

Pain

Lot-to-lot variation of Matrigel™ and the regulatory risk of animal-derived materials, surface-antigen damage from trypsin passaging, and the inability to observe suspension cells in an adherent state — each becomes a critical barrier at GMP transition.

Value

An animal-free recombinant substrate delivers lot reproducibility and GMP readiness. The EGF cassette reduces exogenous EGF in the media, and enzyme-free detachment preserves surface antigens.

Decision-driving data

Cell culture substrate market

$17B → $27.6B (2032, CAGR 7.0%)

Regulatory tailwind

FDA Modernization Act 2.0 / PMDA animal-free trend

Evidence

Kawakami et al. 2025 (peer-reviewed)

Pain

PMMA bone cement's exotherm (>70°C) and residual MMA toxicity, materials that cannot bond in wet fields, impaired bone regeneration, and soft tissue that is hard to suture — all constrain the surgeon's wet-field workflow.

Value

Delivers 63 kPa tensile strength in wet conditions (roughly 30× fibrin glue), with no exotherm and no impairment of bone regeneration. Compounded with β-TCP it becomes a bone putty for void filling.

Decision-driving data

Bone & dental cement market

$1.2–3.1B → $1.6–4.3B (2030)

Preclinical

AMED study confirmed no impairment of bone regeneration

IP

JP filed / PCT filed

Pain

Insufficient mucosal residence time, local formulations that wash away, and the lack of a retention mechanism for endoscopic local therapy — the active ingredient escapes before it reaches the target.

Value

Retains on mucosa for 24+ hours and enables targeted delivery to EGFR-expressing tissue. The cassette architecture turns the adhesive itself into a drug carrier.

Decision-driving data

Drug delivery market

$1,888B → $3,496B (2032, CAGR 8.0%)

Extensibility

Functional domains / drugs fused into the cassette

Stage

Concept & design (seeking co-development)

Pain

Is the platform genuinely differentiated? Does it extend beyond a single market? Is the technology independently validated? Is it protected by IP? — the information needed for an investment or partnership decision.

Value

A single platform that satisfies animal-free, cassette extensibility and wet adhesion at once, extending across cell culture, bone adhesion and DDS. Backed by a peer-reviewed paper and public-fund validation.

Decision-driving data

Combined TAM

Cell culture + bone/dental + DDS — multiple growing markets

Third-party validation

AMED translational research (Kyoto / Hokkaido) & many awards

Base paper

Kawakami et al. 2025 (Materials & Design)